SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is trending as community members discuss its recent listing and availability on Phantom Wallet. The Solana-based token is being touted for its potential gains, with many highlighting its strong momentum and comparing it to other meme coins. Some users note its relative stability amidst broader market volatility.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The meme coin $CAW, also known as crow with knife, is trending as the community buzzes about its multichain presence across Solana, BSC, CRO, and ETH, plus its deflationary mechanism. Community members highlight its organic growth and partnerships, while also mentioning staking opportunities may be coming.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as the community rallies behind it as the top memecoin on Bitcoin, emphasizing its fair launch and strong community-driven nature. Discussions highlight its potential to outperform other memecoins and its unique position within the Bitcoin ecosystem. Community members are actively promoting its listing on major exchanges and emphasizing its potential for significant growth.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is trending due to a collaboration with Kyowa Kirin to develop and commercialize ziftomenib, with the community debating the deal's long-term impact despite a recent milestone payment. Discussions also involve comparing Kura's safety profile to competitors like $SNDX and anticipating potential FDA approval, with some speculating on a possible buyout. Bullish sentiment stems from ziftomenib's potential in treating acute myeloid leukemia and the company's strong cash position.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending amidst discussions on tariffs, CPI, and their potential impact, with community members debating whether previous losses have been recovered adequately. Chatter includes short interest, potential revenue beats, and forward-looking market valuation. The stock is also reacting to broader market forces like gold price fluctuations and sector-specific news from competitors.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF ($BTC) is buzzing as Bitcoin flirts with all-time highs, driven by potential regulatory shifts and growing institutional interest. Community members are closely watching key resistance levels and debating whether Bitcoin's surge will continue or if a correction is on the horizon. The focus remains on Bitcoin's potential as both a safe haven and a growth asset amid economic uncertainty.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending as the community debates its potential to break key resistance levels amid general market volatility, with some expressing frustration over its price action relative to Bitcoin and Binance Coin. There's also buzz around the coin's association with memecoins and upcoming catalysts like potential ETF approval and new partnerships for the Cronos chain. Community members are weighing the potential impact of these developments on CRO's price.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending amid anticipation for its Super App release and upcoming listings on major exchanges like Coinbase and Binance. The community is bullish, drawing comparisons to XRP and highlighting potential NBA and NHL sponsorships. Discussions also involve the project's utility in payroll and staking rewards through Uphold.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to its licensing deal with Vanqua Bio for an oral C5aR1 antagonist, signaling renewed interest in the C5aR pathway; the community is actively discussing the implications of this deal for InflaRx ($IFRX) and other companies in the sector. Discussions involve speculation on potential revenue and the competitive landscape. Also of interest are Biogen's earnings, drug pipeline, and potential for growth.

Teledyne Technologies, Inc. engages in the provision of electronic and communication products for wireless and satellite systems. It operates through the following business segments: Instrumentation, Digital Imaging, Aerospace and Defense Electronics, and Engineered Systems. The Instrumentation segment provides monitoring and control instruments for marine, environmental, industrial, and other applications, and electronic test and measurement equipment. The Digital Imaging segment includes high-performance sensors, cameras, and systems within the visible, infrared, ultraviolet, and X-ray spectra. The Aerospace and Defense Electronics segment offers electronic components and subsystems, data acquisition and communications components and equipment, harsh environment interconnects, and general aviation batteries. The Engineered Systems segment consists of systems engineering, integration and advanced technology development, and complex manufacturing solutions. The company was founded in 1960 and is headquartered in Thousand Oaks, CA.

Teledyne Technologies Inc

Teledyne Technologies ($TDY) is trending due to recent analyst activity, including price target adjustments, and discussions around its growth strategies and performance in the defense and aerospace sectors. The community is focused on the company's potential in areas like drones and AI, as well as its recent earnings and contract wins, with some expressing disappointment in the stock's price movement despite positive news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences to Participate in Upcoming Investor Conference Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire SAN DIEGO, Oct. 16, 2025 SAN DIEGO, Oct. 16, 2025...

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA...

Shares of Avidity Biosciences, Inc. (RNA) fell 20% in the pre-market session on Thursday after the company announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-proposed-public-offering-of-common-stock-302553124.html">stated</a> that it intends to grant the underwriters an option to purchase up to an additional $75 million of shares, while adding that there can be no assurance as to whether or when the offering may be completed.The proceeds of the offering are expected to advance the development of the company’s three late-stage clinical programs, help build appropriate commercial inventory levels to support multiple potential launches, and expand its commercial infrastructure. The company also intends to progress research and development associated with its Antibody Oligonucleotide Conjugates platform and use the proceeds for working capital and general corporate purposes.Avidity had cash, cash equivalents, and marketable securities totaling approximately $1.2 billion as of June 30. It had stated in August that it expects to have sufficient funds for its operations through mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNA">RNA stock</a> rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1360/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_7_16_45_AM_png_8af84254fb.webp" alt="RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="1360" height="122"><figcaption>RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Avidity stock has a good chance of hitting $100 in a year.<stembedurl>https://stocktwits.com/dgbio/message/628258214</stembedurl>The Financial Times <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">reported</a> last month that Novartis made a takeover approach for Avidity, adding that the discussions were at an early stage and might not result in a deal.Avidity has three programs under development for three distinct rare diseases affecting the muscles: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD). Bank of America raised its price target on Avidity to $56 from $54 on Thursday, while maintaining a ‘Buy’ rating on the shares. The firm pinned the price target hike on recent study results, which showed that treatment with Avidity’s Del-zota reversed disease progression in patients with DMD.RNA stock is up by about 60% this year and by about 14% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-cpi-report/chwN03BRdv4">Dow Futures Edge Higher As Wall Street Awaits Consumer Inflation Data: ORCL, OPEN, KLAR, ADBE Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is Avidity Biosciences Stock Down 20% Pre-market Today?

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.

Equity

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.


RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Novartis AG (NVS) has made a takeover approach for San Diego-headquartered Avidity Biosciences (RNA), Financial Times <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/0e2c4788-141c-4dcf-9da9-1c3c6ab9dde1">reported</a> on Wednesday, citing people familiar with the matter.Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, the report said. The discussions are at an early stage and might not result in a deal, sources told FT.However, a takeover for Avidity would probably come with a premium, the people added.Shares of Avidity were trading 22% higher at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNA">Avidity</a> trended in the ‘extremely bullish’ territory over the past 24 hours, coupled with ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1252/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_12_23_34_PM_png_eab16d508a.webp" alt="RNA's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1252" height="126"><figcaption>RNA's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that they do not see the company management selling it for less than $70 or $80 per share, implying a significant premium to current price levels. &nbsp;<stembedurl>https://stocktwits.com/Atomickb/message/623958052</stembedurl>Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘bearish’ to ‘neutral’ over 24 hours, accompanied by ‘normal’ levels of retail chatter.<figure class="image"><img style="aspect-ratio:1254/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_12_23_08_PM_png_0f5356da43.webp" alt="NVS's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1254" height="126"><figcaption>NVS's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> Avidity has three programs under development for three distinct rare diseases affecting the muscles: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD).Novartis, meanwhile, is looking to lose patent protection in the U.S. for some of its best-selling drugs, including heart failure drug Entresto and Xolair, used to treat several allergic conditions.In February, Novartis also agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company, for $925 million upfront.While NYSE-listed shares of Novartis are up by 17% this year, RNA stock soared 60%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/marco-rubio-swiss-president-discuss-39-tariffs-on-switzerland/chrScI0Rd5K">Marco Rubio, Swiss President Discuss 39% Tariffs On Switzerland</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium

Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, FT reported.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	0.00%
50-Day Moving Average	$45.83
Beta	1.18
Avg. Volume	4.06M
PE Ratio	-13.82

52-Week High	$56.00
52-Week Low	$21.51
Market Capitalization	$7.17B
EPS (Annual)	-$2.89
Price to Book	4.98
Revenue Per Employee	$27,869.56
Enterprise Value/EBITDA	N/A

RNA
Avidity Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RNA News

RNAAvidity Biosciences Inc